文献速递真菌感染新发突发、热带与寄生虫病

重症监护室COVID-19相关侵袭性真菌病的国家诊断策略

A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit.
PubMed 文献 · Clin Infect Dis · 2021-01-01

一项多中心前瞻性队列评估强化检测策略在COVID-19重症监护患者中诊断侵袭性真菌病。

要点

  • COVID-19机械通气患者真菌病发生率为26.7%。
  • 合并真菌病者死亡率53%,无真菌病者31%。
  • 接受抗真菌治疗者死亡率38.5%,未治疗者90%。

核心结论

  • 真菌病在重症机械通气的COVID-19患者中频繁发生。
  • 接受抗真菌治疗的患者观察到生存获益,提示所提出的诊断和定义标准是合适的。

研究设计与样本

  • 国家多中心前瞻性队列评估,采用强化检测策略诊断COVID-19重症监护患者的侵袭性真菌病。

主要发现

  • 真菌病发生率为26.7%,其中曲霉病14.1%,酵母菌感染12.6%。
  • 总死亡率为38%;合并真菌病患者死亡率为53%,无真菌病者为31%(P = .0387)。
  • 接受抗真菌治疗者死亡率为38.5%,未接受治疗者为90%(P = .008)。
  • 使用皮质类固醇(P = .007)和慢性呼吸系统疾病史(P = .05)增加曲霉病可能性。

关键数值与推荐

  • 真菌病发生率26.7%(曲霉病14.1%,酵母菌感染12.6%)。
  • 合并真菌病死亡率53% vs 无真菌病31%(P = .0387)。
  • 抗真菌治疗者死亡率38.5% vs 未治疗者90%(P = .008)。
  • 皮质类固醇使用P = .007,慢性呼吸系统疾病史P = .05与曲霉病风险相关。

临床怎么用

  • 对重症机械通气的COVID-19患者应采用策略性诊断方法筛查侵袭性真菌病。
  • 对存在风险因素(使用皮质类固醇、慢性呼吸系统疾病史)的患者可考虑抗真菌预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fungal coinfection is a recognized complication of respiratory virus infections, increasing morbidity and mortality, but can be readily treated if diagnosed early. An increasing number of small studies describing aspergillosis in coronavirus disease 2019 (COVID-19) patients with severe respiratory distress are being reported, but comprehensive data are lacking. The aim of this study was to determine the incidence, risk factors, and impact of invasive fungal disease in adult COVID-19 patients with severe respiratory distress. METHODS: An evaluation of a national, multicenter, prospective cohort evaluation of an enhanced testing strategy to diagnose invasive fungal disease in COVID-19 intensive care patients. Results were used to generate a mechanism to define aspergillosis in future COVID-19 patients. RESULTS: One-hundred and thirty-five adults (median age: 57, M/F: 2.2/1) were screened. The incidence was 26.7% (14.1% aspergillosis, 12.6% yeast infections). The overall mortality rate was 38%; 53% and 31% in patients with and without fungal disease, respectively (P = .0387). The mortality rate was reduced by the use of antifungal therapy (mortality: 38.5% in patients receiving therapy vs 90% in patients not receiving therapy (P = .008). The use of corticosteroids (P = .007) and history of chronic respiratory disease (P = .05) increased the likelihood of aspergillosis. CONCLUSIONS: Fungal disease occurs frequently in critically ill, mechanically ventilated COVID-19 patients. The survival benefit observed in patients receiving antifungal therapy implies that the proposed diagnostic and defining criteria are appropriate. Screening using a strategic diagnostic approach and antifungal prophylaxis of patients with risk factors will likely enhance the management of COVID-19 patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. White PL, Dhillon R, Cordey A, et al. A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit. Clin Infect Dis. 2021. PMID: 32860682. doi:10.1093/cid/ciaa1298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。